Fucoxanthin alleviates glucocorticoid-induced osteoblast apoptosis by activating nuclear factor erythroid-2-related factor 2

doi:10.12307/2024.416

Abstract

Abstract: BACKGROUND: Osteoporosis has a high incidence, leading to fracture and other complications. However, existing drugs have great side effects and are difficult to meet the clinical application.
OBJECTIVE: To explore the effect and potential mechanism of fucoxanthin on osteoporosis induced by glucocorticoid.
METHODS: Primary rat osteoblasts were inoculated in 6-well plates. When the cell fusion reached 80%, the cells were divided into four groups: the control group was cultured alone for 24 hours, the glucocorticoid group was intervened with dexamethasone for 24 hours, the fucoxanthin group was intervened with fucoxanthin for 24 hours, and the glucocorticoid + fucoxanthin group was intervened with dexamethasone and fucoxanthin at the same time for 24 hours. After intervention, cell proliferation, apoptosis, intracellular reactive oxygen species level, and protein expression of apoptosis-related proteins, bone formation-related proteins, and nuclear factor erythroid-2-related factor 2 were detected.
RESULTS AND CONCLUSION: Cell counting kit-8 results showed that the cell viability was decreased in the glucocorticoid group compared with the control group (P < 0.05) but increased in the glucocorticoid+fucoxanthin group compared with the glucocorticoid group (P < 0.05). JC-1 mitochondrial membrane potential staining and flow cytometry assay showed that the percentage of apoptosis increased in the glucocorticoid group compared with the control group (P < 0.05) but decreased in the glucocorticoid+fucoxanthin group compared with the glucocorticoid group (P < 0.05). Western blot assay showed that compared with the control group, the protein expression of BAX and cleaved poly (ADP-ribose) polymerase was elevated in the glucocorticoid group (P < 0.05), and the protein expression of BCL2, type I collagen α1 peptide chain, alkaline phosphatase, osteocalcin, and RUNX2 was decreased in the glucocorticoid group (P < 0.05). Compared with the glucocorticoid group, the protein expression of BAX and cleaved poly (ADP-ribose) polymerase was decreased (P < 0.05), and the protein expression of BCL2, type I collagen α1 peptide chain, alkaline phosphatase, osteocalcin, and RUNX2 was elevated (P < 0.05) in the glucocorticoid+fucoxanthin group. Fluorescent probe assay showed an increase in reactive oxygen species level in the glucocorticoid group compared with the control group (P < 0.05) and a decrease in reactive oxygen species level in the glucocorticoid+fucoxanthin group compared with the glucocorticoid group (P < 0.05). Immunofluorescence staining and western blot assay showed that the protein expression of nuclear factor erythroid-2-related factor 2 in the glucocorticoid group was decreased compared with that in the control group (P < 0.05); and the protein expression of nuclear factor erythroid-2-related factor 2 in the glucocorticoid+fucoxanthin group was elevated compared with that in the glucocorticoid group (P < 0.05). To conclude, fucoxanthin can improve glucocorticoid-induced osteoblast apoptosis and the expression of bone formation-related molecules by activating nuclear factor erythroid-2-related factor 2.

Key words: osteoporosis, glucocorticoid, osteoblast, apoptosis, fucoxanthin, reactive oxygen species, nuclear factor erythroid-2-related factor 2, nuclear translocation

CLC Number:

Xie Ting, Liu Tingting, Zeng Xuehui, Li Yamin, Zhou Panghu, Yi Nianhua. Fucoxanthin alleviates glucocorticoid-induced osteoblast apoptosis by activating nuclear factor erythroid-2-related factor 2[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(23): 3609-3614.

Figures/Tables 9

References

[1] LORENTZONAND M, CUMMINGS SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015;277(6): 650-661.
[2] RAISZAND LG, PRESTWOOD KM. Epidemiology and pathogenesis of osteoporosis. Clin Cornerstone. 2000;2(6):1-10.
[3] 国家卫生健康委员会官网.国家卫生健康委发布首个中国骨质疏松症症流行病学调查结果[J].人口文摘,2018(11): 55-56.
[4] HUANG J, YE Y, XIAO Y, et al. Geniposide ameliorates glucocorticoid-induced osteoblast apoptosis by activating autophagy. Biomed Pharmacother. 2022;155:113829.
[5] HAN D, GU X, GAO J, et al. Chlorogenic acid promotes the Nrf2/HO-1 anti-oxidative pathway by activating p21(Waf1/Cip1) to resist dexamethasone-induced apoptosis in osteoblastic cells. Free Radic Biol Med. 2019;137:1-12.
[6] IBANEZ L, FERRANDIZ ML, BRINES R, et al. Effects of Nrf2 deficiency on bone microarchitecture in an experimental model of osteoporosis. Oxid Med Cell Longev. 2014;2014:726590.
[7] LOBODA A, DAMULEWICZ M, PYZA E, et al. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. 2016;73(17):3221-3247.
[8] WEIVODA MM, CHEW CK, MONROE DG, et al. Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nature Communications. 2020;11(1):87.
[9] JOBKE B, MILOVANOVIC P, AMLINGAND M, et al. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone. 2014;59:37-43.
[10] OTTO S, ABU-ID MH, FEDELE S, et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study. J Craniomaxillofac Surg. 2011;39(4):272-277.
[11] YAMAGUCHI M. Role of carotenoid beta-cryptoxanthin in bone homeostasis. J Biomed Sci. 2012;19(1):36.
[12] RAOAND AV, AGARWAL S. Role of antioxidant lycopene in cancer and heart disease. J Am Coll Nutr. 2000;19(5):563-569.
[13] AGARWALAND S, RAO AV. Tomato lycopene and its role in human health and chronic diseases. CMAJ. 2000;163(6):739-744.
[14] FUJII H, NODA T, SAIRENCHIAND T, et al. Daily intake of green and yellow vegetables is effective for maintaining bone mass in young women. Tohoku J Exp Med. 2009;218(2): 149-154.
[15] YANG Z, ZHANG Z, PENNISTON KL, et al. Serum carotenoid concentrations in postmenopausal women from the United States with and without osteoporosis. Int J Vitam Nutr Res. 2008;78(3):105-111.
[16] CHENG D, ZHANG Y, LIU H, et al. An improving method for extracting total carotenoids in an aquatic animal Chlamys nobilis. Food Chem. 2019;280:45-50.
[17] WANG S, WU S, YANG G, et al. A review on the progress, challenges and prospects in commercializing microalgal fucoxanthin. Biotechnol Adv. 2021;53:107865.
[18] LOURENCO-LOPES C, FRAGA-CORRAL M, JIMENEZ-LOPEZ C, et al. Biological action mechanisms of fucoxanthin extracted from algae for application in food and cosmetic industries. Trends Food Sci Technol. 2021;117:163-181.
[19] DAS SK, REN R, HASHIMOTOAND T, et al. Fucoxanthin induces apoptosis in osteoclast-like cells differentiated from RAW264.7 cells. J Agric Food Chem. 2010;58(10):6090-6095.
[20] HA YJ, CHOI YS, OH YR, et al. Fucoxanthin Suppresses Osteoclastogenesis via Modulation of MAP Kinase and Nrf2 Signaling. Mar Drugs. 2021;19(3):132.
[21] KOSE O, ARABACI T, YEMENOGLU H, et al. Influences of Fucoxanthin on Alveolar Bone Resorption in Induced Periodontitis in Rat Molars. Mar Drugs. 2016;14(4):70.
[22] OLAGNIER D, FARAHANI E, THYRSTED J, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate (vol 11, 4938, 2020). Nat Commun. 2020;11(1):4938.
[23] CHANDLER H, BROOKS DJ, HATTERSLEY G, et al. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. Osteoporos Int. 2019;30(8):1607-1616.
[24] YANG YS, XIE J, WANG D, et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat Commun. 2019;10(1):2958.
[25] BORUMANDI F, AGHALOO T, CASCARINI L, et al. Anti-resorptive Drugs and their Impact on Maxillofacial Bone among Cancer Patients. Anticancer Agents Med Chem. 2015;15(6):736-743.
[26] JIANG M, LIU R, LIU L, et al. Identification of osteogenic progenitor cell-targeted peptides that augment bone formation. Nat Commun. 2020;11(1):4278.
[27] REIDAND IR, BILLINGTON EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399(10329):1080-1092.
[28] SAAG KG, PETERSEN J, BRANDI ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417-1427.
[29] LANGDAHL BL, HOFBAUERAND LC, FORFAR JC. Cardiovascular Safety and Sclerostin Inhibition. J Clin Endocrinol Metab. 2021;106(7):1845-1853.
[30] DE CASTRO LF, MICHEL Z, PAN K, et al. Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone. N Engl J Med. 2023;388(8):766-768.
[31] MERESSE S, FODIL M, FLEURYAND F, et al. Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy. Int J Mol Sci. 2020;21(23):9273.
[32] GAMMONEAND MA, D’ORAZIO N. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar Drugs. 2015;13(4):2196-2214.
[33] LIU M, LI W, CHEN Y, et al. Fucoxanthin: A promising compound for human inflammation-related diseases. Life Sci. 2020;255:117850.
[34] KOYAMA T. Extracts of marine algae show inhibitory activity against osteoclast differentiation. Adv Food Nutr Res. 2011;64:443-454.
[35] WALSH PJ, MCGRATH S, MCKELVEY S, et al. The Osteogenic Potential of Brown Seaweed Extracts. Mar Drugs. 2019;17(3):141.
[36] JOSHI A, IYENGAR R, JOO JH, et al. Nuclear ULK1 promotes cell death in response to oxidative stress through PARP1. Cell Death Differ. 2016;23(2):216-230.
[37] SCHLUTER KS, WOLF A, WEBER M, et al. Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way. Basic Res Cardiol. 2017;112(6):63.
[38] SEBASTIAN S, ZHU YX, BRAGGIO E, et al. Multiple myeloma cells’ capacity to decompose H(2)O(2) determines lenalidomide sensitivity. Blood. 2017;129(8):991-1007.
[39] CHENG KY, GUO F, LU JQ, et al. MnTM-4-PyP modulates endogenous antioxidant responses and protects primary cortical neurons against oxidative stress. CNS Neurosci Ther. 2015;21(5):435-445.
[40] DENG S, DAI G, CHEN S, et al. Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3beta signaling pathway. Biomed Pharmacother. 2019;110:602-608.
[41] LIU X, LIN X, ZHANG S, et al. Lycopene ameliorates oxidative stress in the aging chicken ovary via activation of Nrf2/HO-1 pathway. Aging (Albany NY). 2018;10(8):2016-2036.
[42] NITURE SK, KHATRIAND R, JAISWAL AK. Regulation of Nrf2-an update. Free Radic Biol Med. 2014;66:36-44.
[43] KOKOT A, METZE D, MOUCHET N, et al. Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology. 2009;150(7):3197-3206.
[44] WANG Y, WU H, XIN Y, et al. Sulforaphane Prevents Angiotensin II-Induced Testicular Cell Death via Activation of NRF2. Oxid Med Cell Longev. 2017;2017:5374897.
[45] CHEN X, ZHU X, WEI A, et al. Nrf2 epigenetic derepression induced by running exercise protects against osteoporosis. Bone Res. 2021;9(1):15.
[46] XU P, LIN B, DENG X, et al. VDR activation attenuates osteoblastic ferroptosis and senescence by stimulating the Nrf2/GPX4 pathway in age-related osteoporosis. Free Radic Biol Med. 2022;193(Pt 2):720-735.
[47] GUO J, REN R, GUO Z, et al. Probucol suppresses osteoclastogenesis via activating Nrf2 signaling and ameliorates ovariectomy-induced bone loss. Int Immunopharmacol. 2023;116:109820.
[48] MORATILLA-RIVERA I, SANCHEZ M, VALDES-GONZALEZAND JA, et al. Natural Products as Modulators of Nrf2 Signaling Pathway in Neuroprotection. Int J Mol Sci. 2023;24(4):3748.